An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Afya Limited operates as a medical education group in Brazil.
VERDICT
The label
Markdown
read at $13.90
Afya Limited holds its Markdown at $13.90.
PHPhase · the trend structure carries the Markdown label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-19
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 3 days
Price
$13.90
Valuation
8.63 trailing · 6.96 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.35
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$13.90
8.63 P/E · 6.96 fwd
Our fair value
$20.36
47% discount
Analyst target (avg)
$16.29
+17% to current
Target low $14.55Analyst target rangeTarget high $21.09
▲ current $13.90 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$13.90
you are here
Conservative
$20.36
+46%
Analyst avg
$16.29
+17%
Our fair value
$20.36
+46%
Analyst high
$21.09
+52%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
8.20%
Profit margin
20.07%
Debt to equity
66.89
Analyst consensus
None · 9 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
It depends which standard you follow. There are two widely recognised ways to check whether a company is suitable for a Muslim investor, and on this company they disagree. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✗ DOES NOT PASS
Our stricter standard· asset-based The one Titan applies✓ PASSES
Why the two disagree. They fall out over one thing only: the company’s debt. Our stricter standard measures that debt against what the company owns, and it works out too high to pass. The common standard measures the same debt against what the company is worth on the stock market, where it works out low enough to pass. Every other check, the two agree on. So in practice, most halal apps would treat this as fine to hold, while our stricter view would not — and which line you follow is between you and your scholar.
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is of its assets, above the one-third ceiling the screen allows. Against market value it is 251.9%, under the 30% line the market-value standard uses — so that standard clears it.Divergent
Interest-bearing cashInterest-bearing cash and securities are of assets, above the one-third limit.Fail
ReceivablesMoney owed to the company is of assets, above the 49% limit.Fail
Revenue purityOnly 0.0% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Brazilian Medical Training Trades Below Fair Value
Every year fresh medical students across Brazil queue for places that shape entire careers, and Afya supplies the classrooms and clinical training that make those places possible. The numbers show a defensive business delivering 20% profit margins, 17% returns on equity and 8% revenue growth while the shares sit at a forward multiple of just 7 times earnings.
That valuation leaves a 46% gap to our $20.36 fair value and clears the ethical screen cleanly, yet the opportunity rating stays at none. Unknown competitive protection and a median analyst target of only $16 suggest the market is already discounting execution risk in a single-country education franchise.
Brazilian currency moves and shifting rules on medical-school licences remain live threats that could compress those margins quickly. The low multiple may simply reflect capped growth rather than a mispriced defensive compounder.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Brazil and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
PEERS
Related securities · others in AFYA's space worth a look
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
AFYA trades on Nasdaq (the company is based in Brazil). As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 14%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (9 analysts) rates it underperform, with a mean price target of $17. Entered 2026-07-20 · Markdown
JOURNAL
The dated journal · newest first, never edited
2026-07-20Markdown$13.90-1.4%Entry 5
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 14%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (9 analysts) rates it underperform, with a mean price target of $17.
2026-07-18Markdown$14.10+0.0%Entry 4
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 14%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (9 analysts) rates it underperform, with a mean price target of $17.
2026-07-16Markdown$14.10+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 14%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (9 analysts) rates it underperform, with a mean price target of $17.
2026-07-03Markdown$14.10+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markdown$14.10Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$14.01
+5.0%
·
$1,050
+5.0%
2 months
$15.07
-2.4%
·
$976
-2.4%
3 months
$12.93
+13.8%
$0.66
$1,189
+18.9%
6 months
$13.84
+6.3%
$0.66
$1,110
+11.0%
1 year
$17.01
-13.5%
$0.66
$903
-9.7%
2 years
$15.00
-2.0%
$0.89
$1,040
+4.0%
3 years
$12.18
+20.8%
$0.89
$1,281
+28.1%
5 years
$23.87
-38.4%
$0.89
$653
-34.7%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever AFYA does next, these words stay.
Afya Limited · AFYA · Markdown · $13.90
Recorded 2026-07-19 · before the outcome · scored mechanically
